Moleculin Biotech, Inc MBRX Stock Chart Technical Analysis for 04-16-2020

April 16, 2020

ClayTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk.

Spotlight

Navitor Pharmaceuticals

Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth.

OTHER VIDEOS

Peptides From Phage Display Library Modulate Gene Expression In Mesenchymal Cells

video | June 8, 2022

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects - a 2 minute Preview of the Experimental Protocol Gary Balian, Gina Beck, Vedavathi Madhu, Robert Sikes, Quanjun Cui, Haixiang Liang, Joshua Bush University of Virginia, Orthopaedics Research; University of Delaware, Biological Sciences; University of Virginia, Orthopaedic Surgery; A phage display library was used to identify peptide sequences that target bone. The objective was to investigate the effect of these peptides on mesenchymal cell differentiation and to determine their effect on bone regeneration....

Watch Now

Would a society based on genetics be… good?

video | June 15, 2022

Eugenics is the practice of using "planned breeding" for "racial improvement." Because this idea is repulsive, the predominant response has been "genome blindness” — that is, avoiding any study or discussion of genetic differences between people. But according to geneticist Paige Harden, this is the wrong solution. Instead, we should identify genetic differences between people — including those that might affect social outcomes — so that we can help provide people with the resources they need to be successful....

Watch Now

mRNA Therapy for Fragile X Syndrome

video | June 2, 2022

Dr. Kathryn Whitehead, Associate Professor at Carnegie Mellon University, helped develop the revolutionary science behind the COVID-19 vaccines. With a 2 year $100,000 grant from FRAXA, her team will now adapt mRNA technology to deliver the missing Fragile X protein, to treat people who have Fragile X syndrome....

Watch Now

What is mRNA, and how does it work?

video | March 21, 2022

mRNA is the key ingredient in COVID-19 vaccines. But what is it, and how does it work? Associate Professor John McGhee and his team at UNSW’s 3D Visualisation Aesthetics Lab have created a visually immersive 3D animation to explore mRNA’s role in our cells – and to show how it helps fight COVID-19....

Watch Now

Spotlight

Navitor Pharmaceuticals

Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth.

Events